STAT3 and cancer: One way to prevent STAT-3 activation is to inhibit thetyrosine kinase events at receptor level, which is unfeasible in most cancers.(Jing and Tweardy, 2005; Quesnelle et al., 2007;Boehm et al., 2008;Wilks, 2008; Egloff and Grandis, 2009; Sen et al., 2009a; Santos et al., 2010; Verstovsek et al., 2010).